Literature DB >> 2146511

Circulating CD8+ cytotoxic T lymphocytes specific for HTLV-I pX in patients with HTLV-I associated neurological disease.

S Jacobson1, H Shida, D E McFarlin, A S Fauci, S Koenig.   

Abstract

The human T-lymphotropic virus type I (HTLV-I), the first human retrovirus to be characterized, is associated with adult T-cell leukaemia and a chronic progressive disease of the central nervous system termed tropical spastic paraparesis, or HTLV-I-associated myelopathy. Only 1% of individuals infected with HTLV-I develop clinical disease however. The various manifestations of an HTLV-I infection may be related to differences in the genetic backgrounds of individuals, infection with variant strains of HTLV-I, differences in viral tropism or host immune response to the virus. Whereas the humoral response to HTLV-I is well characterized, little is known about the human cellular immune response, such as the production of cytotoxic T lymphocytes. Here we report the presence of high levels of circulating HTLV-I-specific cytotoxic T lymphocytes in patients with HTLV-I associated neurological disease but not in HTLV-I seropositive individuals without neurological involvement. These cytotoxic T lymphocytes are CD8+, HLA class I- restricted and predominantly recognize the HTLV-I gene products encoded in the regulatory region pX. These findings suggest that HTLV-I-specific cytotoxic T lymphocytes may contribute to the pathogenesis of associated neurological disorders associated with HTLV-I.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2146511     DOI: 10.1038/348245a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  208 in total

1.  The distinction blurs between an autoimmune versus microbial hypothesis in multiple sclerosis.

Authors:  D A Hafler
Journal:  J Clin Invest       Date:  1999-09       Impact factor: 14.808

2.  IL-15 plays a major role in the persistence of Tax-specific CD8 cells in HAM/TSP patients.

Authors:  N Azimi; M Nagai; S Jacobson; T A Waldmann
Journal:  Proc Natl Acad Sci U S A       Date:  2001-11-20       Impact factor: 11.205

3.  Selected cytotoxic T lymphocytes with high specificity for HTLV-I in cerebrospinal fluid from a HAM/TSP patient.

Authors:  Ryuji Kubota; Samantha S Soldan; Roland Martin; Steven Jacobson
Journal:  J Neurovirol       Date:  2002-02       Impact factor: 2.643

4.  Marked suppression of T cells by a benzothiophene derivative in patients with human T-lymphotropic virus type I-associated myelopathy/tropical spastic paraparesis.

Authors:  M Makino; M Azuma; S I Wakamatsu; Y Suruga; S Izumo; M M Yokoyama; M Baba
Journal:  Clin Diagn Lab Immunol       Date:  1999-05

5.  High frequency of virus-specific CD8+ T cells in the central nervous system of macaques chronically infected with simian immunodeficiency virus SIVmac251.

Authors:  Marcin Moniuszko; Charlie Brown; Ranajit Pal; Elzbieta Tryniszewska; Wen-Po Tsai; Vanessa M Hirsch; Genoveffa Franchini
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

Review 6.  Neuroimmunity of HTLV-I Infection.

Authors:  Eiji Matsuura; Yoshihisa Yamano; Steven Jacobson
Journal:  J Neuroimmune Pharmacol       Date:  2010-05-02       Impact factor: 4.147

Review 7.  Human T-lymphotropic virus type 1 (HTLV-1): persistence and immune control.

Authors:  Charles R M Bangham
Journal:  Int J Hematol       Date:  2003-11       Impact factor: 2.490

Review 8.  Leukemogenesis of adult T-cell leukemia.

Authors:  Jun-ichirou Yasunaga; Masao Matsuoka
Journal:  Int J Hematol       Date:  2003-11       Impact factor: 2.490

Review 9.  T-cell control by human T-cell leukemia/lymphoma virus type 1.

Authors:  Genoveffa Franchini; Risaku Fukumoto; Jake R Fullen
Journal:  Int J Hematol       Date:  2003-11       Impact factor: 2.490

10.  Clonal expansion of CD8+ cytotoxic T lymphocytes against human T cell lymphotropic virus type I (HTLV-I) genome products in HTLV-I-associated myelopathy/tropical spastic paraparesis patients.

Authors:  K Furukawa; M Mori; N Ohta; H Ikeda; H Shida; K Furukawa; H Shiku
Journal:  J Clin Invest       Date:  1994-11       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.